Autolus plans expansion of AUCATZYL centers in 2025 to cover 90% of U.S. patients
2025-03-20 11:56:55 ET
More on Autolus Therapeutics
- Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript
- Autolus Therapeutics plc 2024 Q4 - Results - Earnings Call Presentation
- Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
- Autolus Therapeutics FY 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Autolus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Autolus plans expansion of AUCATZYL centers in 2025 to cover 90% of U.S. patientsNASDAQ: AUTL
AUTL Trading
22.54% G/L:
$1.93 Last:
4,124,476 Volume:
$1.62 Open:










